Hubbard et al, Safety and activity of PolyPEPI1018 combined with maintenance therapy in metastatic colorectal cancer: an open-label, multicenter, phase 1b study

Table S2: Summary of PolyPEPI1018-induced immune responses based on measured IVS ELISpot assay results

mmunological responses	Number of patients % (n/N)
CD8 ⁺ T cell responses	•
Pre-existing	70% (7/10)
De novo	80% (8/10)
Post-vaccination (boosted + de novo)	90% (9/10)
Against ≥ 3 TAAs	80% (8/10)
CD4 ⁺ T cell responses	
Pre-existing	100 % (10/10)
Post-vaccination	100% (10/10)
CD8 ⁺ and CD4 ⁺ T cell responses	90% (9/10)

TAA: Tumor-associated antigen targeted by the vaccine; pre-existing: detected before vaccination; *de novo*: detected only after vaccination; boosted: at least two-fold increase in magnitude compared to pre-vaccination T cell responses. Related to Figure 3A and B.